Exon dosage analysis of parkin gene in Chinese sporadic Parkinson's disease

被引:15
|
作者
Guo, Ji-Feng [1 ,2 ,3 ,4 ]
Dong, Xiao-Li [1 ]
Xu, Qian [1 ]
Li, Nan [1 ]
Yan, Xin-Xiang [1 ,3 ,4 ]
Xia, Kun [2 ]
Tang, Bei-Sha [1 ,3 ,4 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha 410008, Hunan, Peoples R China
[2] State Key Lab Med Genet, Changsha 410008, Hunan, Peoples R China
[3] Key Lab Hunan Prov Neurodegenerat Disorders, Changsha 410008, Hunan, Peoples R China
[4] Cent S Univ, Neurodegenerat Disorders Res Ctr, Changsha 410008, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
Parkinson's disease; Parkin gene; MLPA; Exon rearrangement; Gene mutation; EARLY-ONSET PARKINSONISM; MUTATIONS; POPULATION; EUROPE;
D O I
10.1016/j.neulet.2015.07.046
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkin gene mutations are by far the most common mutations in both familial Parkinson's disease (PD) and sporadic PD. Approximately, 50% of parkin mutations is exon dosage mutations (i.e., deletions and duplications of entire exons). Here, we first established a MLPA assay for quick detection of parkin exon rearrangements. Then, we studied parkin exon dosage mutations in 755 Chinese sporadic PDdisease patients using the established MLPA assay. We found that there were 25 (3.3%) patients with exon dosage alterations including deletions and duplications, 20 (11.4%) patients with exon rearrangements in 178 early-onset patients, and 5 (0.86%) patients with exon rearrangement mutations in 579 later-onset patients. The percentage of individuals with parkin dosage mutations is more than 33% when the age at onset is less than 30 years old, but less than 7% when the age at onset is more than 30. In these mutations, deletion is the main mutational style, especially in exon 2-5. Our results indicated that exon dosage mutations in parkin gene might be the main cause for sporadic PD, especially in EOP. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 50 条
  • [31] Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation
    Sharp, Madeleine E.
    Marder, Karen S.
    Cote, Lucien
    Clark, Lorraine N.
    Nichols, William C.
    Vonsattel, Jean-Paul
    Alcalay, Roy N.
    MOVEMENT DISORDERS, 2014, 29 (04) : 566 - 568
  • [32] Association of VEGF gene polymorphisms with sporadic Parkinson's disease in Chinese Han population
    Wu, Yubin
    Zhang, Yingying
    Han, Xun
    Li, Xiaoyuan
    Xue, Li
    Xie, Anmu
    NEUROLOGICAL SCIENCES, 2016, 37 (12) : 1923 - 1929
  • [33] Association of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population
    Gao, Jing
    Teng, Jijun
    Liu, Hongxin
    Han, Xun
    Chen, Biao
    Xie, Anmu
    NEUROSCIENCE LETTERS, 2014, 559 : 158 - 162
  • [34] Gene dosage analysis of α-synuclein (SNCA) in patients with Parkinson's disease
    Deng, H
    Xie, WJ
    Guo, Y
    Le, WD
    Jankovic, J
    MOVEMENT DISORDERS, 2006, 21 (05) : 728 - 729
  • [35] NO parkin in Parkinson's disease
    Lancaster, JR
    SCIENCE, 2004, 304 (5679) : 1905 - 1905
  • [36] Parkin gene mutations in young onset Parkinson's disease
    Tan, EK
    Shen, H
    Zhao, Y
    Hu, WP
    Pavanni, R
    Wong, MC
    MOVEMENT DISORDERS, 2002, 17 : S36 - S36
  • [37] Parkin gene therapy could treat Parkinson's disease
    Butcher, J
    LANCET NEUROLOGY, 2005, 4 (02): : 82 - 82
  • [38] Parkin and Parkinson's disease
    Mizuno, Y
    Hattori, N
    Mori, H
    Suzuki, T
    Tanaka, K
    CURRENT OPINION IN NEUROLOGY, 2001, 14 (04) : 477 - 482
  • [39] Parkin gene mutations in Brazilian patients with Parkinson's disease
    Iwamoto, FM
    Teive, HA
    Raskin, S
    Alan, N
    Quagliato, E
    Werneck, LC
    Brice, A
    NEUROLOGY, 2001, 56 (08) : A126 - A127
  • [40] Early-onset Parkinson's disease and the Parkin gene
    Matas, IF
    Alvarez, VM
    Coto, E
    Ribacoba, R
    Guisasola, L
    Salvador, C
    MOVEMENT DISORDERS, 2002, 17 : S33 - S34